bluebird bio, Inc. (NASDAQ:BLUE) to Post Q2 2024 Earnings of ($0.41) Per Share, William Blair Forecasts

bluebird bio, Inc. (NASDAQ:BLUE) – William Blair lifted their Q2 2024 earnings estimates for bluebird bio in a research note issued to investors on Tuesday, September 24th. William Blair analyst S. Corwin now anticipates that the biotechnology company will post earnings of ($0.41) per share for the quarter, up from their prior estimate of ($0.63). The consensus estimate for bluebird bio’s current full-year earnings is ($1.57) per share. William Blair also issued estimates for bluebird bio’s Q3 2024 earnings at ($0.39) EPS, Q4 2024 earnings at ($0.43) EPS, FY2024 earnings at ($1.58) EPS, Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at $0.01 EPS, Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($0.80) EPS.

A number of other research analysts also recently commented on BLUE. Barclays dropped their price objective on shares of bluebird bio from $8.00 to $4.00 and set an “overweight” rating for the company in a research note on Thursday, August 15th. StockNews.com started coverage on bluebird bio in a report on Friday. They issued a “sell” rating for the company. Bank of America dropped their price objective on bluebird bio from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday, August 15th. Wells Fargo & Company decreased their price target on shares of bluebird bio from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Wednesday. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of bluebird bio in a research note on Monday, September 16th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, bluebird bio currently has a consensus rating of “Hold” and an average target price of $4.63.

bluebird bio Stock Up 1.4 %

BLUE opened at $0.50 on Friday. The business’s fifty day simple moving average is $0.77 and its 200 day simple moving average is $0.97. The company has a quick ratio of 0.82, a current ratio of 0.93 and a debt-to-equity ratio of 0.20. The firm has a market cap of $55.15 million, a P/E ratio of -0.68 and a beta of 0.75. bluebird bio has a 52 week low of $0.46 and a 52 week high of $5.53.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Allegheny Financial Group LTD bought a new stake in bluebird bio in the second quarter valued at approximately $25,000. Dynamic Technology Lab Private Ltd acquired a new stake in bluebird bio during the 4th quarter valued at $37,000. Enterprise Bank & Trust Co acquired a new position in shares of bluebird bio in the first quarter valued at $38,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of bluebird bio by 189.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 36,580 shares of the biotechnology company’s stock worth $47,000 after buying an additional 23,933 shares during the last quarter. Finally, Sequoia Financial Advisors LLC boosted its holdings in shares of bluebird bio by 48.0% during the 1st quarter. Sequoia Financial Advisors LLC now owns 40,085 shares of the biotechnology company’s stock worth $51,000 after buying an additional 13,000 shares during the period. Institutional investors and hedge funds own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.